A bispecific T-cell engager (BiTE) antibody construct that binds CD19 on B-ALL cells and CD3 on T cells to redirect T-cell cytotoxicity against CD19-positive leukemic blasts.
A BiTE antibody construct that simultaneously binds CD19 on B-lineage cells and CD3 on T cells, physically bridging T cells to CD19+ targets to trigger T-cell activation and cytolytic killing (perforin/granzyme–mediated) of CD19-expressing leukemic blasts independent of native TCR specificity.
YES
DIRECT
Blinatumomab bridges CD3+ T cells to CD19+ cells, activating T-cell cytotoxicity and perforin/granzyme-mediated killing of CD19-expressing targets.
A bispecific T-cell engager (BiTE) antibody construct that binds CD19 on B-ALL cells and CD3 on T cells to redirect T-cell cytotoxicity against CD19-positive leukemic blasts.
A BiTE antibody construct that simultaneously binds CD19 on B-lineage cells and CD3 on T cells, physically bridging T cells to CD19+ targets to trigger T-cell activation and cytolytic killing (perforin/granzyme–mediated) of CD19-expressing leukemic blasts independent of native TCR specificity.
NO
INDIRECT
Blinatumomab binds CD3ε on T cells to activate and redirect them to kill CD19+ cells via perforin/granzyme; the CD3ε+ T cells themselves are not targeted for killing.
A humanized, full-length bispecific IgG2 kappa antibody (Elrexfio) that redirects T cells by binding BCMA on multiple myeloma cells and CD3 on T cells, forming an immune synapse to activate TCR/CD3 signaling and induce T cell–mediated cytotoxicity and cytokine release against BCMA-positive cells.
Elranatamab is a humanized bispecific antibody that binds BCMA on multiple myeloma cells and CD3 on T cells, crosslinking them to form an immune synapse, activate TCR/CD3 signaling, and induce T cell–mediated cytotoxicity and cytokine release against BCMA-positive cells.
YES
DIRECT
Elranatamab bridges CD3+ T cells to BCMA-expressing cells, forming an immune synapse that activates T cells to kill the target via perforin/granzyme-mediated cytolysis and apoptosis.
A humanized, full-length bispecific IgG2 kappa antibody (Elrexfio) that redirects T cells by binding BCMA on multiple myeloma cells and CD3 on T cells, forming an immune synapse to activate TCR/CD3 signaling and induce T cell–mediated cytotoxicity and cytokine release against BCMA-positive cells.
Elranatamab is a humanized bispecific antibody that binds BCMA on multiple myeloma cells and CD3 on T cells, crosslinking them to form an immune synapse, activate TCR/CD3 signaling, and induce T cell–mediated cytotoxicity and cytokine release against BCMA-positive cells.
NO
INDIRECT
Elranatamab binds CD3 on T cells to activate and redirect them to kill BCMA-positive tumor cells; CD3+ cells are not targeted for killing.